We exceeded our outlook and delivered a solid performance in Q3 2024. Learn more 👉 https://lnkd.in/eZ3CHdXZ ◾ Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57. ➡ Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER. ➡ +10% CER growth in Diagnostic solutions leads results among product groups. ➡ 29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023. ➡ Free cash flow up 73% to $364 million in first nine months of 2024 vs. same 2023 period. ◾ FY 2024 net sales outlook reaffirmed for at least $1.985 billion CER on solid core business trends; adj. diluted EPS outlook increased to at least $2.19 CER.
Congratulations!
Keep growing
Congratulations QIAGEN...
Great news
Congrats!
Médico Patologista Clínico na HEMOES
3mo👍👍👏👏❤️❤️